Third quarter (July - September 2025)

• Net sales in the third quarter were 16,6 (9,8) MSEK, an increase of 70%.
• Operating profit in the quarter amounted to -1,2 (-5,1) MSEK. The improvement can be explained by the sales increase during the quarter, and personnel costs and operating expenditures following plan. 
• Profit for the quarter was -1,4 (-5,3) MSEK.
• Cash flow from operating activities was -7,1 (-6,6) MSEK.
• The order intake for the third quarter was 10,0 (3,1) MSEK, an increase of 6,9 MSEK.
• Personnel costs and other external costs in total increased 3% during the quarter to      13,6 (13,2) MSEK.
• Other operating costs had a negative impact during the quarter, -0,1 (-0,1) MSEK.
• Earnings per share in the quarter amounted to -0,02 (-0,12) SEK - before and after dilution. 
• Cash and cash equivalents at the end of the period were 21,5 (47,9) MSEK.

Message from the CEO

The third quarter of 2025 marks a clearly positive development for Bio-Works.
With a 70% increase in sales and an improved operating result, we are demonstrating that our strategy is working. The measures we have taken to strengthen sales and improve operational efficiency are now bearing fruit. 

The launch of WorkBeads™ affimAb Edge is an important milestone. With this new premium resin, we are reinforcing our position within affinity chromatography and meeting the growing demand from the global biopharmaceutical industry. The product opens doors that were previously closed and is generating great interest among both existing and potential new customers.

We continue our focused work toward profitability. Our determined efforts to establish Bio-Works as a key player in oligonucleotide purification are beginning to show tangible results. At the same time, we are strengthening customer relationships in all regions and building long-term partnerships that form the foundation for future growth.

Our production team has completed the investment we announced earlier this year. As a result, we have eliminated bottlenecks and doubled our production capacity. In parallel, we continue to find new and innovative ways to increase capacity in a resource-efficient and sustainable manner, creating a more robust and flexible supply chain that benefits our customers and strengthens our market position.

Our focus is to keep the level of operating expenditure stable despite the strong increase in sales, and we see potential for further improvement in profitability ahead. We enter the final quarter of the year with a solid order book, a growing customer base, and strong confidence in our direction going forward.

To all customers and shareholders - thank you for your continued confidence. To all our employees - thank you for your commitment and focus on continuous improvement. Together we are building a profitable and innovative Bio-Works. 

Lone Carlbom

CEO Bio-Works Technologies AB

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge, CFO, e-mail: arne.hauge@bio-works.com, phone: +46(0)8-502 705 83.

About Bio-Works
Bio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our ambition is to be a trusted and dynamic partner in an industry characterized by growth and development.

Bio-Works' headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market ("BIOWKS"). For more information, visit www.bio-works.com.